(Q51809092)

12 April 2018

title

Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. (English)

1 reference

12 April 2018

main subject

Malawi

0 references

anti-retroviral agent

0 references

1 reference

12 April 2018

Christopher Brasher

1 reference

12 April 2018

Bruno Spire

object named as

Bruno Spire

1 reference

12 April 2018

Jacques Izopet

1 reference

12 April 2018

Nathan Ford

1 reference

12 April 2018

author name string

Laurent Ferradini

1 reference

12 April 2018

Arnaud Jeannin

1 reference

12 April 2018

Loretxu Pinoges

1 reference

12 April 2018

Didakus Odhiambo

1 reference

12 April 2018

Limangeni Mankhambo

1 reference

12 April 2018

Gloria Karungi

1 reference

12 April 2018

Elisabeth Szumilin

1 reference

12 April 2018

Serge Balandine

1 reference

12 April 2018

Gaëlle Fedida

1 reference

12 April 2018

M Patrizia Carrieri

1 reference

12 April 2018

Jean-Michel Tassie

1 reference

12 April 2018

language of work or name

English

0 references

publication date

1 April 2006

1 reference

12 April 2018

published in

The Lancet

1 reference

12 April 2018

volume

367

1 reference

12 April 2018

issue

9519

1 reference

12 April 2018

page(s)

1335-1342

1 reference

12 April 2018

Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968580-2

7 January 2021

Using RT-PCR and bDNA assays to measure non-clade B HIV-1 subtype RNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968580-2

7 January 2021

Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968580-2

7 January 2021

Evolution of human immunodeficiency virus type 1 populations after resumption of therapy following treatment interruption and shift in resistance genotype

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968580-2

7 January 2021

Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AAC

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968580-2

7 January 2021

Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968580-2

7 January 2021

The Dynamic of Adherence to Highly Active Antiretroviral Therapy: Results From the French National APROCO Cohort

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968580-2

7 January 2021

The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968580-2

7 January 2021

Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968580-2

7 January 2021

Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968580-2

7 January 2021

Scaling-up HIV treatment programmes in resource-limited settings: the rural Haiti experience

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968580-2

7 January 2021

Cohort Profile: Antiretroviral Therapy in Lower Income Countries (ART-LINC): international collaboration of treatment cohorts

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968580-2

7 January 2021

The safety, tolerability and effectiveness of generic antiretroviral drug regimens for HIV-infected patients in south India

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968580-2

7 January 2021

Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968580-2

7 January 2021

Access to antiretroviral drugs in Brazil

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968580-2

7 January 2021

Antiretroviral treatment in resource-poor settings: the Brazilian experience

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968580-2

7 January 2021

Dramatic improvement in survival among adult Brazilian AIDS patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968580-2

7 January 2021

Decline in the AIDS and death rates in the EuroSIDA study: an observational study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968580-2

7 January 2021

Immune restoration disease after antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968580-2

7 January 2021

Weight loss and survival in HIV-positive patients in the era of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968580-2

7 January 2021

Body mass index at time of HIV diagnosis: a strong and independent predictor of survival.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968580-2

7 January 2021

Promoting adherence to antiretroviral therapy: the experience from a primary care setting in Khayelitsha, South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968580-2

7 January 2021

Adherence is not a barrier to successful antiretroviral therapy in South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968580-2

7 January 2021

Treatment of antiretroviral-drug-resistant HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968580-2

7 January 2021

High levels of adherence do not prevent accumulation of HIV drug resistance mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968580-2

7 January 2021

Drug resistance and adherence to HIV/AIDS antiretroviral treatment: against a double standard between the north and the south

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968580-2

7 January 2021

Extending antiretroviral therapy to resource-poor settings: implications for drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968580-2

7 January 2021

What policymakers should know about drug resistance and adherence in the context of scaling-up treatment of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968580-2

7 January 2021

High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Côte d'Ivoire

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968580-2

7 January 2021

Scaling up access to antiretroviral treatment in southern Africa: who will do the job?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2968580-2

7 January 2021

10.1016/S0140-6736(06)68580-2

Identifiers

DOI

1 reference

12 April 2018

1 reference

12 April 2018